Table 1.
Participant characteristics
| Controls (n=319) |
Cases | |||
|---|---|---|---|---|
| Alla lung cancers (n=319) |
Non-small cell lung cancerb (n=240) |
Small cell lung cancer (n=68) |
||
| Matching variables | ||||
| Age at blood draw, mean years (SD) | 63.5 (5.7) | 64.5 (5.6) | 64.5 (5.5) | 64.5 (5.8) |
| 45–54, n (%) | 21 (7) | 21 (7) | 16 (7) | 4 (6) |
| 55–59, n (%) | 77 (24) | 42 (13) | 31 (13) | 9 (13) |
| 60–64, n (%) | 86 (27) | 101 (32) | 77 (32) | 23 (34) |
| 65–74, n (%) | 135 (42) | 155 (49) | 116 (48) | 32 (47) |
| Sex, n (%) female | 109 (34) | 109 (34) | 78 (33) | 28 (41) |
| Enrollment year, n (%) |
13 (4) 13 (4) 79 (25) 146 (46) 68 (21) |
15 (5) 14 (4) 78 (24) 144 (45) 68 (21) |
13 (5) 9 (4) 57 (24) 107 (45) 54 (22) |
2 (3) 4 (6) 16 (24) 33 (49) 13 (19) |
| 1985–1986 | ||||
| 1987–1988 | ||||
| 1989–1990 | ||||
| 1991–1992 | ||||
| 1993–1994 | ||||
| Asbestos exposure, n (%) | 53 (17) | 52 (16) | 42 (18) | 9 (13) |
| Current smoker at blood draw, n (%) | 205 (64) | 206 (65) | 155 (65) | 41 (60) |
| Other characteristics at blood draw | ||||
| Stage III/IVc, n (%) | - | 197 (73) | 143 (67) | 53 (95) |
| Cigarettes per day, lifetime mean (SD) | 14.0 (13.3) | 15.5 (15.0) | 15.0 (14.7) | 15.7 (15.7) |
| Pack-years, mean (SD) | 53.8 (23.7) | 59.3 (22.5) | 58.5 (22.2) | 60.1 (22.9) |
| Years since quit smoking, mean (SD) | 2.4 (5.0) | 2.3 (4.3) | 2.4 (4.3) | 2.5 (4.3) |
| BMI (kg/m2), mean (SD) | 28.1 (5.6) | 27.7 (4.9) | 27.6 (4.8) | 28.1 (5.4) |
| <18.5 (%) | 4 (1) | 2 (1) | 2 (1) | -- |
| 18.5–24.9 (%) | 85 (27) | 92 (29) | 69 (29) | 19 (28) |
| 25.0–29.9 (%) | 130 (41) | 136 (43) | 101 (42) | 30 (44) |
| ≥30.0 (%) | 100 (31) | 89 (28) | 68 (28) | 19 (28) |
| Intervention arm, n (%) assigned to active | 168 (53) | 166 (52) | 123 (51) | 39 (57) |
| mdNLR at blood draw | ||||
| Mean (SD) | 1.86 (0.90) | 2.06 (1.31) | 2.07 (1.31) | 1.88 (1.21) |
Abbreviations: SD = Standard Deviation; BMI = Body Mass Index.
a
”All lung cancers” includes adenocarcinoma, squamous cell carcinoma, and small cell lung cancer as well as cases for whom histotype was not otherwise specified non-small cell lung cancer (NOS; n=9) or missing (n=11).
b
The “Non-small cell lung cancer” category includes adenocarcinoma, squamous cell carcinoma, and not otherwise specified non-small cell lung cancer (NOS; n=9).
c
Stage information was not available for 50 lung cancer cases (28 NSCLC, 12 SCLC, and 10 missing histotype).